HIV and Hepatitis Research Unit, Department of Virology, Sefako Makgatho Health Sciences University and National Health Laboratory Service, Medunsa, Pretoria, South Africa.
South African Medical Research Council, Pretoria, South Africa.
J Med Virol. 2018 Feb;90(2):291-303. doi: 10.1002/jmv.24956. Epub 2017 Nov 13.
We investigated how the natural course of occult hepatitis B virus (HBV) infection (OBI) may evolve during HIV co-infection and long term HBV-active HAART. From a cohort of 181 HIV infected patients who were consecutively recruited over a 5 year period, 28 HBV co-infected patients with sequential sera (n = 98) were identified. Iterative HBV serology and viral loads were determined before and during treatment. The viral HBsAg gene was then serially amplified, directly sequenced, and molecularly characterized. Persistent detection of anti-HBs did not result in a modification to the clinical course of OBI. In contrast, reactivation of chronic HBV infection, hepatic enzymatic flares and cases of HBV reinfection were evident among anti-HBs negative OBI patients, and this was a notable finding. Of the 14 chronic HBV infected patients, eight progressed to persistent OBI after initiation of HBV-active HAART, increasing the number of patients with OBI in the study. Long term HBV-active HAART was not found to have a notable impact on low level viremia during OBI. While the HBsAg gene sequences isolated from chronic HBV infection were genetically stable over time, OBI-associated variants (sP111R, sT127P, sY161F) were neither stable nor predominant during the course of infection. This study is the first of its kind from South Africa to show the occurrence of hepatic enzymatic flares, HBV reactivation, and reinfection in HAART-exposed HIV co-infected patients with OBI. Among the cases studied, there was further evidence that OBI-associated variants may not play a significant role in the pathogenesis of OBI.
我们研究了隐匿性乙型肝炎病毒(HBV)感染(OBI)在 HIV 合并感染和长期 HBV 活性抗逆转录病毒治疗(HAART)期间的自然病程会如何演变。在连续 5 年内,我们从 181 名 HIV 感染患者中招募了一个队列,其中有 28 名 HBV 合并感染患者,他们有连续的血清样本(n=98)。在治疗前后,我们反复进行 HBV 血清学和病毒载量检测。然后,我们对病毒 HBsAg 基因进行连续扩增、直接测序和分子特征分析。持续检测到抗-HBs 并没有改变 OBI 的临床病程。相比之下,在抗-HBs 阴性的 OBI 患者中,慢性 HBV 感染的再激活、肝酶学 flares 和 HBV 再感染的情况很明显,这是一个显著的发现。在 14 名慢性 HBV 感染患者中,有 8 名在开始 HBV 活性 HAART 后进展为持续性 OBI,这增加了研究中 OBI 患者的数量。长期的 HBV 活性 HAART 并没有显著影响 OBI 期间的低水平病毒血症。虽然从慢性 HBV 感染中分离的 HBsAg 基因序列随时间推移保持遗传稳定,但在感染过程中,OBI 相关变异(sP111R、sT127P、sY161F)既不稳定也不占主导地位。这项来自南非的研究是首例显示在接受 HAART 的 HIV 合并感染的 OBI 患者中发生肝酶学 flares、HBV 再激活和再感染的研究。在研究的病例中,进一步的证据表明,OBI 相关变异可能在 OBI 的发病机制中不起重要作用。